F. Baekelandt MD, W. Everaerts MD, PhD, M. Albersen MD, PhD, B. Van Cleynenbreugel MD, PhD, U. Milenkovic MD, C. Assenmacher MD, S. Joniau MD, PhD
BRCA2 mutation carriers generally present with prostate cancer at a younger age, with more aggressive disease and with a higher risk of nodal involvement or distant metastases at diagnosis. We present a patient with metastatic castrate resistant prostate cancer with a BRCA2 gene mutation and its clinical significance for daily practice.
H. Van Den Bossche MD, R. Kokx MD, M. Albersen MD, PhD, C. Assenmacher MD, H. Van Poppel MD, PhD, S. Joniau MD, PhD
High-intensity focused ultrasound has been used as an alternative treatment for prostate cancer, as both primary or salvage treatment. It is considered a minimally invasive treatment modality. We recently needed to care for two patients with severe osteomyelitis of the pubic bone as a result of a prostatopubic fistula, after they underwent salvage high-intensity focused ultrasound treatment post-radiotherapy.